Join
Live feed
·
PRReleasevia Quantisnow
Tvardi Therapeutics Inc. logo

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

ByQuantisnow·Wall Street's wire, on your screen.
TVRD· Tvardi Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TVRD (Tvardi Therapeutics Inc.) and more on Quantisnow.